

Appl. No. 09/214,851
Response dated December 7, 2005
Reply to Office action of November 2, 2005

Amendments to Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-18 (Cancelled)

19. (Currently Amended) A method of enhancing inhibition of nicotine metabolism by a CYP2A6 inhibitor in an individual comprising administering to the individual an effective amount of a substance which selectively inhibits CYP2A6, and an effective amount of an inhibitor of CYP2A6, wherein the substance is at least one member selected from the group consisting of coumarin, furanocoumarin, methoxsalen, imperatorin, psoralen, α -naphthoflavone, isopimpinellin, β -naphthoflavone, bergapten, sphondin, coumatetralyl (raeumin), (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidim-4-one, naringenin, diethyldithiocarbamate, N-nitrosodialkylamine, nitropyrene, menadione, imidazole antimycotics, miconazole, clotrimazole, pilocarpine, hexamethylphosphoramide, 4-methylnitrosamine-3-pyridyl-1-butanol, aflatoxin B, and analogs and derivatives of coumarin or methoxsalen.

20. (Original) The method defined in claim 19, wherein the N-nitrosodialkylamine is selected from the group consisting of N-nitrosodiethylamine, N-nitrosodimethylamine and mixtures thereof.

Claims 21-22 (Cancelled)

23. (Currently Amended) A pharmaceutical composition for regulating the metabolism of nicotine to cotinine comprising an effective amount of a substance which selectively inhibits CYP2A6 and an effective amount of an inhibitor of CYP2A6, wherein the

Appl. No. 09/214,851
Response dated December 7, 2005
Reply to Office action of November 2, 2005

substance comprises at least one member selected from the group consisting of coumarin, furanocoumarin, methoxsalen, imperatorin, psoralen, α -naphthoflavone, isopimpinellin, β -naphthoflavone, bergapten, sphondin, coumatetralyl (racumin), (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidim-4-one, naringenin, diethyldithiocarbamate, N-nitrosodialkylamine, nitropyrene, menadione, imidazole antimycotics, miconazole, clotrimazole, pilocarpine, hexamethylphosphoramide, 4-methylnitrosamine-3-pyridyl-1-butanol, aflatoxin B, and analogs and derivatives of coumarin or methoxsalen, and mixtures thereof.

24. (Original) The composition defined in claim 23, wherein the N-nitrosodialkylamine is selected from the group consisting of N-nitrosodiethylamine, N-nitrosodimethylamine and mixtures thereof.

Claims 25-26 (Cancelled)

27. (Currently Amended) A method for treating a condition requiring regulation of nicotine metabolism to cotinine in an individual comprising administering to the individual an effective amount of a substance which selectively inhibits CYP2A6, and an effective amount of an inhibitor of CYP2A6, wherein the substance is at least one member selected from the group consisting of coumarin, furacoumarin, methoxsalen, imperatorin, psoralen, α -naphthoflavone, isopimpinellin, β -naphthoflavone, bergapten, sphondin, coumatetralyl (racumin), (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidim-4-one, naringenin, diethyldithiocarbamate, N-nitrosodialkylamine, nitropyrene, menadione, imidazole, antimycotics, miconazole, clotrimazole, pilocarpine, hexamethylphosphoramide, 4-methylnitrosamine-3-pyridyl-1-butanol, aflatoxin B, and analogs and derivatives of coumarin or methoxsalen, and mixtures thereof; and wherein the condition requiring regulation of nicotine metabolism is dependent tobacco use.

Appl. No. 09/214,851
Response dated December 7, 2005
Reply to Office action of November 2, 2005

28. (Original) The method defined in claim 27, wherein the N-nitrosodialkylamine is selected from the group consisting of N-nitrosodiethylamine, N-nitrosodimethylamine and mixtures thereof.

Claims 29-38 (Cancelled)

39. (Previously Presented) The method of claim 19, wherein the substance is methoxsalen or a derivative thereof.

40. (Previously Presented) The method of claim 27, wherein the substance is methoxsalen or a derivative thereof.

41. (Previously Presented) The method of claim 23, wherein the substance is methoxsalen or a derivative thereof.

Claims 42-46 (Cancelled)